Alexey Danilov, M.D., Ph.D. | City of Hope

Dr. Alexey V. Danilov

Claim this profile

City of Hope Medical Center

Studies Mantle Cell Lymphoma
Studies Chronic Lymphocytic Leukemia
9 reported clinical trials
15 drugs studied

Area of expertise

1

Mantle Cell Lymphoma

Alexey V. Danilov has run 4 trials for Mantle Cell Lymphoma. Some of their research focus areas include:

CCND1 positive
del(17p) positive
TP53 positive
2

Chronic Lymphocytic Leukemia

Alexey V. Danilov has run 4 trials for Chronic Lymphocytic Leukemia. Some of their research focus areas include:

13q positive
13q negative
12 positive

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope Comprehensive Cancer Center

Clinical Trials Alexey V. Danilov is currently running

Image of trial facility.

Nemtabrutinib + Rituximab

for Mantle Cell Lymphoma

This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

Zanubrutinib + Odronextamab

for Richter's Transformation

This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is a bispecific monoclonal antibody that can bind to two different antigens at the same time. Odronextamab binds to CD20 found on B-cells (a type of white blood cell) and on many B-cell cancers and to CD3 on T-cells (also a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving zanubrutinib in combination with odronextamab may be safe, tolerable and/or effective in treating patients with Richter's transformation.

Recruiting

1 award

Phase 1

15 criteria

More about Alexey V. Danilov

Clinical Trial Related

3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Alexey V. Danilov has experience with

  • Rituximab
  • Venetoclax
  • Odronextamab
  • Zanubrutinib
  • Acalabrutinib
  • Ublituximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Alexey V. Danilov specialize in?

Is Alexey V. Danilov currently recruiting for clinical trials?

Are there any treatments that Alexey V. Danilov has studied deeply?

What is the best way to schedule an appointment with Alexey V. Danilov?

What is the office address of Alexey V. Danilov?

Is there any support for travel costs?